From: An in vitro toolbox to accelerate anti-malarial drug discovery and development
Compound | Fraction unbound ± SD | |||
---|---|---|---|---|
Human Plasmaa | Albumaxa | 10% FCS in DMEMa | HLMa | |
Ionized or partially ionized bases at physiological pH | ||||
 Cycloguanil | 0.75 ± 0.040 | 0.88 ± 0.057 | 0.94 ± 0.064 | 0.72 ± 0.083 |
 Doxycyclin | 0.23 ± 0.090b | 0.41 ± 0.023 | 0.44 ± 0.070 | 0.93 ± 0.045 |
 Pyronaridine | 0.090 ± 0.012b | 0.69 ± 0.023 | Not assessed | 0.29 ± 0.018 |
 Proguanil | 0.34 ± 0.010 | 0.80 ± 0.021 | Not assessed | 0.33 ± 0.014 |
 Primaquine | 0.26 ± 0.023 | 0.96 ± 0.056 | 0.78 ± 0.025 | 0.56 ± 0.050 |
 Chloroquine | 0.54 ± 0.048 | 0.97 ± 0.069 | Not assessed | 0.50 ± 0.032 |
 Chlorproguanil | 0.10 ± 0.0070 | 0.50 ± 0.020 | Not assessed | 0.052 ± 0.004 |
 Azithromycin | 0.34, 0.35b | 0.76 ± 0.065 | Not assessed | 0.70 ± 0.060 |
 AQ-13 | 0.43 ± 0.022 | 0.85 ± 0.028 | Not assessed | 0.66 ± 0.048 |
 Desethylamodiaquine | 0.17 ± 0.0020 | 0.75 ± 0.074 | Not assessed | not assessed |
 Quinine | 0.37 ± 0.040b | 0.69 ± 0.090 | Not assessed | 0.57 ± 0.036 |
 Clindamycin | 0.19 ± 0.011 | 0.65 ± 0.066 | Not assessed | 0.67 ± 0.084 |
 KAF156 | 0.069 ± 0.013b | 0.38 ± 0.017 | 0.477 ± 0.032 | 0.14 ± 0.0060 |
 M5717 | 0.24 ± 0.0020b | 0.55 ± 0.041 | 0.638 ± 0.065 | 0.50 ± 0.041 |
 OZ277 | 0.086 ± 0.0080 | 0.29 ± 0.021 | Not assessed | 0.044 ± 0.0050 |
 Mefloquine | 0.015 ± 0.0010b | 0.27 ± 0.019 | Not assessed | 0.050 ± 0.0060 |
 Amodiaquine | 0.089 ± 0.0080 | 0.67 ± 0.033 | Not assessed | 0.91 ± 0.094 |
 NPC1161B | 0.00074 ± 0.00016c | 0.035 ± 0.0020 | 0.043 ± 0.004 | CNDe |
 Ferroquine | 0.041 ± 0.0010c | 0.52 ± 0.031 | 0.364 ± 0.026 | 0.27 ± 0.032 |
 Naphthoquine | 0.018 ± 0.0010c | 0.27 ± 0.035 | Not assessed | 0.21 ± 0.015 |
 Tafenoquine | 0.00070 ± 0.00017c | CNDe | 0.038 ± 0.001 | 0.0020 ± 0.00030 |
 MMV253 | 0.017 ± 0.00020c | 0.48 ± 0.026 | Not assessed | 0.11 ± 0.017 |
 MMV052 | 0.00040 ± 0.00010c | 0.014 ± 0.0010 | Not assessed | 0.0010 ± 0.00010 |
 Piperaquine | 0.0003 ± 0.0001c | 0.019 ± 0.0040 | 0.092 ± 0.0030 | 0.013 ± 0.0020 |
 Halofantrine | < 0.0001c | 0.0080 ± 0.0010 | Not assessed | 0.0020 ± 0.00020 |
 TDD-E209 | < 0.0001c | 0.0070 ± 0.0010 | Not assessed | 0.00030 ± 0.000010 |
 Lumefantrine | < 0.0001c | CNDe | Not assessed | CNDe |
Ionized acids at physiological pH | ||||
 Sulfadoxine | 0.036 ± 0.0010 | 0.50 ± 0.030 | 0.86 ± 0.044 | 0.93 ± 0.086 |
 Sulfamethoxazole | 0.32 ± 0.024 | 0.67 ± 0.120 | 0.87 ± 0.058 | 1.00 ± 0.033 |
 Artesunate | 0.27 ± 0.0080d | 0.14 ± 0.0070d | 0.72 ± 0.026 | CNDd |
 Atovaquone | < 0.0001c | CNDe | CNDe | ~ 0.0020 |
Zwitterionic or partially zwitterionic at physiological pH | ||||
 P218 | 0.13 ± 0.013 | 0.41 ± 0.022 | 0.684 ± 0.017 | 0.88 ± 0.041 |
 JPC3210 | 0.0028 ± 0.00020c | 0.21 ± 0.012 | 0.227 ± 0.012 | 0.029 ± 0.0030 |
Neutral at physiological pH | ||||
 Dapsone | 0.27 ± 0.019 | 0.63 ± 0.11 | Not assessed | 0.86 ± 0.059 |
 Dihydroartemisinin | 0.21 ± 0.010d | 0.34 ± 0.018d | Not assessed | 0.87 ± 0.10d |
 DSM421 | 0.039 ± 0.007 | 0.43 ± 0.020 | 0.615 ± 0.043 | 0.77 ± 0.065f |
 Pyrimethamine | 0.095 ± 0.0010b | 0.46 ± 0.090 | 0.48 ± 0.034 | 0.54 ± 0.097 |
 MMV048 | 0.11 ± 0.0070b | 0.46 ± 0.022 | 0.653 ± 0.060 | 0.61 ± 0.014 |
 Artemisone | 0.12 ± 0.0060 | 0.46 ± 0.013 | Not assessed | 0.44 ± 0.024 |
 Artemether | 0.038 ± 0.0090c | 0.46 ± 0.039 | Not assessed | 0.50 ± 0.052 |
 SJ733 | 0.085 ± 0.012c | 0.40 ± 0.040 | Not assessed | 0.58 ± 0.069 |
 DSM265 | 0.0018 ± 0.00010c | 0.18 ± 0.0050f | 0.366 ± 0.041 | 0.28 ± 0.0070f |
 KAE609 | 0.0016 ± 0.00010c | 0.044 ± 0.0040 | Not assessed | 0.019 ± 0.0010 |
 OZ439 | < 0.0001c | 0.010 ± 0.0010 | Not assessed | 0.0010 ± 0.00010 |
 ELQ300 | 0.00010 ± 0.000010c | CNDe | 0.001 ± 0.001 | 0.002 ± 0.00010 |